{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:41:15Z","timestamp":1791600075153,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recent studies have shown that sodium-glucose cotransporter-2 inhibitors (SGLT2i) can achieve significant improvement in blood pressure in people with diabetes. Furthermore, randomized controlled trials (RCTs) have established that SGLT2i have a cardioprotective effect in adults with heart failure (HF). Therefore, we performed this systematic review an meta-analysis to determine the effect of SGLT2i on blood pressure in patients with HF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used the Medline, Cochrane Library, Embase, and PubMed databases to identify RCTs (published through to April 29, 2022) that evaluated the effect of SGLT2i on HF. The primary endpoint was defined as change in blood pressure. Secondary composite outcomes were heart rate, hematocrit, body weight, and glycated hemoglobin. The N-terminal pro-brain natriuretic peptide level, Kansas City Cardiomyopathy Questionnaire scores, and estimated glomerular filtration rate were also evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After a literature search and detailed evaluation, 16 RCTs were included in the quantitative analysis. Pooled analyses showed that SGLT2i were associated with a statistically significant reduction in systolic blood pressure of 1.68\u00a0mmHg (95% confidence interval [CI] \u2212\u00a02.7, \u2212\u00a00.66; P\u2009=\u20090.001; I<jats:sup>2<\/jats:sup>\u2009=\u200945%) but not diastolic blood pressure (mean difference [MD] \u22121.06\u00a0mmHg; 95% CI \u22123.20, 1.08; P\u2009=\u20090.33; I<jats:sup>2<\/jats:sup>\u2009=\u200943%) in comparison with controls. Furthermore, SGLT2i decreased body weight (MD \u2212\u00a01.36\u00a0kg, 95% CI \u2212\u00a01.68, \u2212\u00a01.03; P\u2009&lt;\u20090.001; I<jats:sup>2<\/jats:sup>\u2009=\u200961%) and the glycated hemoglobin level (MD \u2212\u00a00.16%, 95% CI \u2212\u00a00.28, \u22120.04, P\u2009=\u20090.007; I<jats:sup>2<\/jats:sup>\u2009=\u200991%) but increased hematocrit (MD 1.63%, 95% CI 0.63, 2.62, P\u2009=\u20090.001; I<jats:sup>2<\/jats:sup>\u2009=\u2009100%). There was no significant between-group difference in heart rate (MD \u2212\u00a00.35; 95% CI \u2212\u00a02.05, 1.35, P\u2009=\u20090.69; I<jats:sup>2<\/jats:sup>\u2009=\u20090).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>SGLT2i decreased systolic blood pressure in patients with HF but had no effect on diastolic blood pressure. These inhibitors may have numerous potentially beneficial clinical effects in patients with HF.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-022-01574-w","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T14:04:02Z","timestamp":1658757842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Min","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tieci","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"key":"1574_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"},{"key":"1574_CR2","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","volume":"175","author":"Y Gerber","year":"2015","unstructured":"Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175:996\u20131004.","journal-title":"JAMA Intern Med"},{"key":"1574_CR3","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"1574_CR4","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324.","journal-title":"N Engl J Med"},{"key":"1574_CR5","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","volume":"61","author":"MC Thomas","year":"2018","unstructured":"Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018;61:2098\u2013107.","journal-title":"Diabetologia"},{"key":"1574_CR6","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1111\/dom.14451","volume":"23","author":"A Tsapas","year":"2021","unstructured":"Tsapas A, Karagiannis T, Kakotrichi P, Avgerinos I, Mantsiou C, Tousinas G, et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab. 2021;23:2116\u201324.","journal-title":"Diabetes Obes Metab"},{"key":"1574_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005686","author":"WL Baker","year":"2017","unstructured":"Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, et al. Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2017. https:\/\/doi.org\/10.1161\/JAHA.117.005686.","journal-title":"J Am Heart Assoc"},{"key":"1574_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019463","volume":"10","author":"YH Teo","year":"2021","unstructured":"Teo YH, Teo YN, Syn NL, Kow CS, Yoong CSY, Tan BYQ, et al. Effects of Sodium\/Glucose Cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials. J Am Heart Assoc. 2021;10: e019463.","journal-title":"J Am Heart Assoc"},{"key":"1574_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/ejhf.818","volume":"19","author":"HO Ventura","year":"2017","unstructured":"Ventura HO, Messerli FH, Lavie CJ. Observations on the blood pressure paradox in heart failure. Eur J Heart Fail. 2017;19:843\u20135.","journal-title":"Eur J Heart Fail"},{"key":"1574_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/hrt.2007.134973","volume":"95","author":"CE Raphael","year":"2009","unstructured":"Raphael CE, Whinnett ZI, Davies JE, Fontana M, Ferenczi EA, Manisty CH, et al. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart (British Cardiac Society). 2009;95:56\u201362.","journal-title":"Heart (British Cardiac Society)"},{"key":"1574_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jacc.2006.10.028","volume":"49","author":"MA Pfeffer","year":"2007","unstructured":"Pfeffer MA. Blood pressure in heart failure: a love-hate relationship. J Am Coll Cardiol. 2007;49:40\u20132.","journal-title":"J Am Coll Cardiol"},{"key":"1574_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6: e1000100.","journal-title":"PLoS Med"},{"key":"1574_CR13","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed). 2019;366: l4898.","journal-title":"BMJ (Clinical research ed)"},{"key":"1574_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JPTTJ Higgins","year":"2019","unstructured":"Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions. 2nd ed. Chichester (UK): John Wiley & Sons; 2019.","edition":"2"},{"key":"1574_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327:557\u201360.","journal-title":"BMJ (Clinical research ed)"},{"key":"1574_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004007","author":"M Mazidi","year":"2017","unstructured":"Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of Sodium-Glucose Cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017. https:\/\/doi.org\/10.1161\/JAHA.116.004007.","journal-title":"J Am Heart Assoc"},{"key":"1574_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383\u201394.","journal-title":"J Clin Epidemiol"},{"key":"1574_CR18","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","volume":"142","author":"NA Mordi","year":"2020","unstructured":"Mordi NA, Mordi IR, Singh JS, McCrimmon RJ, Struthers AD, Lang CC. Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial. Circulation. 2020;142:1713\u201324.","journal-title":"Circulation"},{"key":"1574_CR19","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","volume":"140","author":"ME Nassif","year":"2019","unstructured":"Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140:1463\u201376.","journal-title":"Circulation"},{"key":"1574_CR20","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.2337\/dc19-2187","volume":"43","author":"JSS Singh","year":"2020","unstructured":"Singh JSS, Mordi IR, Vickneson K, Fathi A, Donnan PT, Mohan M, et al. Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the REFORM Trial. Diabetes Care. 2020;43:1356\u20139.","journal-title":"Diabetes Care"},{"key":"1574_CR21","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27:1954\u201360.","journal-title":"Nat Med"},{"key":"1574_CR22","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection Fraction. N Engl J Med. 2021;385:1451\u201361.","journal-title":"N Engl J Med"},{"key":"1574_CR23","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","volume":"143","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F, et al. Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation. 2021;143:1673\u201386.","journal-title":"Circulation"},{"key":"1574_CR24","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","volume":"6","author":"M Omar","year":"2021","unstructured":"Omar M, Jensen J, Ali M, Frederiksen PH, Kistorp C, Videb\u00e6k L, et al. Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the empire HF randomized clinical trial. JAMA cardiology. 2021;6:836\u201340.","journal-title":"JAMA cardiology"},{"key":"1574_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12933-021-01410-7","volume":"20","author":"R Pietschner","year":"2021","unstructured":"Pietschner R, Kolwelter J, Bosch A, Striepe K, Jung S, Kannenkeril D, et al. Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. Cardiovasc Diabetol. 2021;20:219.","journal-title":"Cardiovasc Diabetol"},{"key":"1574_CR26","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"MMY Lee","year":"2021","unstructured":"Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143:516\u201325.","journal-title":"Circulation"},{"key":"1574_CR27","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/ehf2.12707","volume":"7","author":"A Tanaka","year":"2020","unstructured":"Tanaka A, Hisauchi I, Taguchi I, Sezai A, Toyoda S, Tomiyama H, et al. Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE). ESC Heart Failure. 2020;7:1585\u201394.","journal-title":"ESC Heart Failure"},{"key":"1574_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3335","volume":"36","author":"S Carbone","year":"2020","unstructured":"Carbone S, Billingsley HE, Canada JM, Bressi E, Rotelli B, Kadariya D, et al. The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study. Diabetes Metab Res Rev. 2020;36: e3335.","journal-title":"Diabetes Metab Res Rev"},{"key":"1574_CR29","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1253\/circrep.CR-21-0030","volume":"3","author":"T Ueda","year":"2021","unstructured":"Ueda T, Kasama S, Yamamoto M, Nakano T, Ueshima K, Morikawa Y, et al. Effect of the sodium-glucose cotransporter 2 inhibitor canagliflozin for heart failure with preserved ejection fraction in patients with type 2 diabetes. Circ Rep. 2021;3:440\u20138.","journal-title":"Circ Rep"},{"key":"1574_CR30","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015103","volume":"9","author":"K Ejiri","year":"2020","unstructured":"Ejiri K, Miyoshi T, Kihara H, Hata Y, Nagano T, Takaishi A, et al. Effect of luseogliflozin on heart failure with preserved ejection fraction in patients with diabetes mellitus. J Am Heart Assoc. 2020;9: e015103.","journal-title":"J Am Heart Assoc"},{"key":"1574_CR31","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/bcp.14248","volume":"86","author":"RA de Boer","year":"2020","unstructured":"de Boer RA, N\u00fa\u00f1ez J, Kozlovski P, Wang Y, Proot P, Keefe D. Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure. Br J Clin Pharmacol. 2020;86:1346\u201356.","journal-title":"Br J Clin Pharmacol"},{"key":"1574_CR32","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","volume":"8","author":"WL Baker","year":"2014","unstructured":"Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens: JAS. 2014;8:262-75.e9.","journal-title":"J Am Soc Hypertens: JAS"},{"key":"1574_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","volume":"75","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33\u201359.","journal-title":"Drugs"},{"key":"1574_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12933-017-0511-0","volume":"16","author":"M Pfeifer","year":"2017","unstructured":"Pfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 2017;16:29.","journal-title":"Cardiovasc Diabetol"},{"key":"1574_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ejphar.2004.10.055","volume":"506","author":"S Villafa\u00f1a","year":"2004","unstructured":"Villafa\u00f1a S, Huang F, Hong E. Role of the sympathetic and renin angiotensin systems in the glucose-induced increase of blood pressure in rats. Eur J Pharmacol. 2004;506:143\u201350.","journal-title":"Eur J Pharmacol"},{"key":"1574_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165703","volume":"11","author":"SJ Shin","year":"2016","unstructured":"Shin SJ, Chung S, Kim SJ, Lee EM, Yoo YH, Kim JW, et al. Effect of sodium-glucose co-transporter 2 Inhibitor, Dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS ONE. 2016;11: e0165703.","journal-title":"PLoS ONE"},{"key":"1574_CR37","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","volume":"715","author":"A Tahara","year":"2013","unstructured":"Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715:246\u201355.","journal-title":"Eur J Pharmacol"},{"key":"1574_CR38","volume":"32","author":"D Chambergo-Michilot","year":"2021","unstructured":"Chambergo-Michilot D, Tauma-Arru\u00e9 A, Loli-Guevara S. Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: a systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2021;32: 100690.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"1574_CR39","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s00228-021-03147-4","volume":"77","author":"YH Teo","year":"2021","unstructured":"Teo YH, Yoong CSY, Syn NL, Teo YN, Cheong JYA, Lim YC, et al. Comparing the clinical outcomes across different sodium\/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2021;77:1453\u201364.","journal-title":"Eur J Clin Pharmacol"},{"key":"1574_CR40","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.cardfail.2008.03.006","volume":"14","author":"L Grigorian-Shamagian","year":"2008","unstructured":"Grigorian-Shamagian L, Gonzalez-JuAnatey JR, Vazquez R, Cinca J, Bayes-Genis A, Pascual D, et al. Association of blood pressure and its evolving changes with the survival of patients with heart failure. J Cardiac Fail. 2008;14:561\u20138.","journal-title":"J Cardiac Fail"},{"key":"1574_CR41","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1093\/eurheartj\/ehaa496","volume":"41","author":"M Serenelli","year":"2020","unstructured":"Serenelli M, B\u00f6hm M, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Eur Heart J. 2020;41:3402\u201318.","journal-title":"Eur Heart J"},{"key":"1574_CR42","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"S Yusuf","year":"1991","unstructured":"Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293\u2013302.","journal-title":"N Engl J Med"},{"key":"1574_CR43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/eurjhf\/hfp195","volume":"12","author":"MT Vid\u00e1n","year":"2010","unstructured":"Vid\u00e1n MT, Bueno H, Wang Y, Schreiner G, Ross JS, Chen J, et al. The relationship between systolic blood pressure on admission and mortality in older patients with heart failure. Eur J Heart Fail. 2010;12:148\u201355.","journal-title":"Eur J Heart Fail"},{"key":"1574_CR44","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.jacc.2016.07.754","volume":"68","author":"JW McEvoy","year":"2016","unstructured":"McEvoy JW, Chen Y, Rawlings A, Hoogeveen RC, Ballantyne CM, Blumenthal RS, et al. Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control. J Am Coll Cardiol. 2016;68:1713\u201322.","journal-title":"J Am Coll Cardiol"},{"key":"1574_CR45","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/jdi.12726","volume":"9","author":"M Sano","year":"2018","unstructured":"Sano M, Chen S, Imazeki H, Ochiai H, Seino Y. Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: subanalysis of placebo-controlled, double-blind clinical trials. J Diabetes Investig. 2018;9:638\u201341.","journal-title":"J Diabetes Investig"},{"key":"1574_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","volume":"19","author":"W Shimizu","year":"2020","unstructured":"Shimizu W, Kubota Y, Hoshika Y, Mozawa K, Tara S, Tokita Y, et al. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol. 2020;19:148.","journal-title":"Cardiovasc Diabetol"},{"key":"1574_CR47","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, et al. How does empagliflozin reduce cardiovascular mortality? insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41:356\u201363.","journal-title":"Diabetes Care"},{"key":"1574_CR48","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"V Vallon","year":"2017","unstructured":"Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60:215\u201325.","journal-title":"Diabetologia"},{"key":"1574_CR49","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/ijcp.12384","volume":"68","author":"JP Wilding","year":"2014","unstructured":"Wilding JP. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract. 2014;68:682\u201391.","journal-title":"Int J Clin Pract"},{"key":"1574_CR50","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/dom.12500","volume":"17","author":"CD Sj\u00f6str\u00f6m","year":"2015","unstructured":"Sj\u00f6str\u00f6m CD, Hashemi M, Sugg J, Ptaszynska A, Johnsson E. Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels. Diabetes Obes Metab. 2015;17:809\u201312.","journal-title":"Diabetes Obes Metab"},{"key":"1574_CR51","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/dmrr.2479","volume":"30","author":"M Zhang","year":"2014","unstructured":"Zhang M, Zhang L, Wu B, Song H, An Z, Li S. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2014;30:204\u201321.","journal-title":"Diabetes Metab Res Rev"},{"key":"1574_CR52","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00228-014-1730-x","volume":"70","author":"XP Yang","year":"2014","unstructured":"Yang XP, Lai D, Zhong XY, Shen HP, Huang YL. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol. 2014;70:1149\u201358.","journal-title":"Eur J Clin Pharmacol"},{"key":"1574_CR53","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/dom.12307","volume":"16","author":"A Liakos","year":"2014","unstructured":"Liakos A, Karagiannis T, Athanasiadou E, Sarigianni M, Mainou M, Papatheodorou K, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:984\u201393.","journal-title":"Diabetes Obes Metab"},{"key":"1574_CR54","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1002\/ejhf.1958","volume":"22","author":"FA McAlister","year":"2020","unstructured":"McAlister FA, Zheng Y, Westerhout CM, Buse JB, Standl E, McGuire DK, et al. Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial. Eur J Heart Fail. 2020;22:2026\u201334.","journal-title":"Eur J Heart Fail"},{"key":"1574_CR55","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/FJC.0000000000001099","volume":"78","author":"DB Shrestha","year":"2021","unstructured":"Shrestha DB, Budhathoki P, Sedhai YR, Karki P, Gurung S, Raut S, et al. Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated systematic review and meta-analysis of 13 randomized clinical trials including 14,618 patients with heart failure. J Cardiovasc Pharmacol. 2021;78:501\u201314.","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01574-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01574-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01574-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T16:04:51Z","timestamp":1658765091000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01574-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1574"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01574-w","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]},"assertion":[{"value":"15 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}